NCT04907370 (DIAMOND) is a Phase 3 clinical trial of PD-1 blocking antibody in Nasopharyngeal Carcinoma, sponsored by Sun Yat-sen University.

Who is sponsoring NCT04907370?

NCT04907370 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT04907370?

Interventions in NCT04907370: PD-1 blocking antibody, Gemcitabine, Cisplatin (80mg/m2), Cisplatin (100mg/m2), Intensity-modulated radiotherapy.

What condition does NCT04907370 study?

NCT04907370 studies Nasopharyngeal Carcinoma.

Is NCT04907370 still recruiting?

NCT04907370 is currently active, enrolled. Last updated 16 July 2025.

Last reviewed 2025-07-16 · How we verify

NCT04907370: DIAMOND

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PD-1 Blockade Combined With De-intensified Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma

Active, enrolled Phase 3 Last updated 16 July 2025

What this trial tests

Phase 3 trial testing PD-1 blocking antibody in Nasopharyngeal Carcinoma in 532 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

1 August 2021

Primary endpoint
1 March 2025

1 March 2027

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	532
Start date	1 August 2021
Primary completion	1 March 2025
Estimated completion	1 March 2027
Sites	12 locations across China

Drugs / interventions tested

PD-1 blocking antibody — full drug profile →
Gemcitabine (gemcitabine) — full drug profile →
Cisplatin (80mg/m2) — full drug profile →
Cisplatin (100mg/m2) — full drug profile →
Intensity-modulated radiotherapy

Conditions studied

Nasopharyngeal Carcinoma — all drugs for Nasopharyngeal Carcinoma →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 65, any sex, with Nasopharyngeal Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 3, multi-center, randomized controlled trial, with the purpose to evaluate the therapeutic efficacy and safety of PD-1 blockade (toripalimab) combined with the de-intensified chemoradiotherapy sparing concurrent cisplatin (i.e., toripalimab incorporated into induction chemotherapy and radiotherapy) in high-risk locoregionally advanced nasopharyngeal carcinoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
Naimi A, Mohammed RN, Raji A, Chupradit S, et al · · 2022 · cited 350× · PMID 35392976 · DOI 10.1186/s12964-022-00854-y
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.
Xu L, Zou C, Zhang S, Chu TSM, et al · · 2022 · cited 131× · PMID 35799264 · DOI 10.1186/s13045-022-01307-2
Advanced Nasopharyngeal Carcinoma: Current and Emerging Treatment Options.
Jiromaru R, Nakagawa T, Yasumatsu R. · · 2022 · cited 42× · PMID 36117730 · DOI 10.2147/cmar.s341472
Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma: The DIAMOND Randomized Clinical Trial.
DIAMOND Study Group, Xu C, Liang XY, Huang XQ, et al · · 2025 · cited 13× · PMID 40839372 · DOI 10.1001/jama.2025.13205
A real-world evaluation of tislelizumab in patients with head and neck cancer.
Zheng B, Huang Z, Liu W, Zhao D, et al · · 2024 · cited 7× · PMID 38482433 · DOI 10.21037/tcr-23-1502
Anti-programmed death-1 inhibitors and nimotuzumab in combination with induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a propensity score-matched analysis.
Zhang YN, Chen YP, OuYang PY, Lu TX, et al · · 2025 · cited 3× · PMID 39896749 · DOI 10.1177/17588359251316094
Immunotherapy in nasopharyngeal carcinoma: current status and unanswered questions.
Liu X, Ma J. · · 2025 · cited 1× · PMID 40242461 · DOI 10.1016/j.lanwpc.2025.101547
Efficacy of PD-1 inhibitor plus induction chemotherapy for nasopharyngeal carcinoma with high-grade extranodal extension: a multicenter retrospective analysis.
Zhou P, Liu X, Huang S, Luo Y, et al · · 2026 · PMID 41987113 · DOI 10.1186/s12885-026-15995-3

Verify or expand the search:

Other trials of PD-1 blocking antibody

Trials testing the same drug.

NCT06239727 — Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response · Phase 3 · recruiting
NCT06195254 — Stereotactic Body Radiotherapy Combined With PD-1 Blockers for Locally Advanced or Locally Recurrent Pancreatic Cancer · completed
NCT03984357 — Nivolumab Combined With Chemoradiotherapy Sparing Concurrent Cisplatin in Nasopharyngeal Carcinoma · Phase 2 · completed

Other recruiting trials for Nasopharyngeal Carcinoma

Currently open trials in the same condition.

NCT06059261 — Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC. · Phase 2 · recruiting
NCT07328854 — 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06912711 — TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma · Phase 2 · recruiting
NCT07000643 — Phase III Non-Inferiority Trial of Proton Versus Photon Therapy for Nasopharyngeal Carcinoma · Phase 3 · recruiting
NCT06682442 — Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma · NA · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04907370 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 16 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04907370.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing